Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.

Revenue projections:

Revenue projections for CAPLIPOINT
Revenue projections for CAPLIPOINT

With CAPLIPOINT's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 0.000000
forwardPE 18.472708
debtToEquity 0.166000
earningsGrowth 0.183000
revenueGrowth 0.101000
grossMargins 0.592320
operatingMargins 0.313960
trailingEps 80.540000
forwardEps 91.600000

CAPLIPOINT's Forward PE is positioned well, reflecting a favorable balance between stock price and earnings. The stock isn't overpriced, offering room for growth and making it a potentially rewarding investment as its value has room to rise further.
CAPLIPOINT's positive earnings and revenue growth point to business expansion on the horizon. The company is positioned for continued success, with increasing profits and revenue growth highlighting a strong path forward for future growth.
Caplin Point Laboratories Limited's positive gross and operating margins indicate a profitable and efficient business model. These metrics highlight the company's ability to generate income while controlling operational costs, reflecting strong financial performance.
Caplin Point Laboratories Limited's forward EPS being higher than its trailing EPS indicates that the company is expected to achieve greater profitability this financial year. This suggests improving earnings and a stronger financial position compared to the previous year's performance.

Price projections:

Price projections for CAPLIPOINT
Price projections for CAPLIPOINT

CAPLIPOINT's price currently reflects projections without revealing significant risks or opportunities. This status quo implies that investors may experience minimal fluctuations in the stock, leading to a cautious approach in trading decisions until future indicators emerge.

Recommendation changes over time:

Recommendations trend for CAPLIPOINT
Recommendations trend for CAPLIPOINT


Analysts' buy bias for CAPLIPOINT signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to CAPLIPOINT, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.